TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Multicenter Trial of Post-Suicide Attempt Case Management for the Prevention of Further Attempts in Japan (ACTION-J)
Brief Summary: This study will determine the effectiveness of continuous follow-up care by case manager in preventing further suicide attempts


Options:
A: Inclusion Criteria:

* Current diagnosis of Axis I anxiety disorder (based on M.I.N.I.)
* Diagnosis of comorbid personality disorder (based on SCID II) or depressive disorder (based on M.I.N.I.)
* Age: 18 to 65 years
* Sufficient knowledge of the Polish language
* Written informed consent of the patient

Exclusion Criteria:

* Organic disorder
* Acute substance related disorders
* Schizophrenia, bipolar affective disorder
* Severe depression \[over 26 points in Beck Questionnaire\] or bipolar disorder.
* Dissocial personality disorder, schizotypal personality disorder
* Current suicidal ideation with a high risk of suicide
* Restriction of intellectual capacity
* Serious unstable medical problems/complications
* Concurrent psychotherapeutic treatment
* Failed treatment of CBT or psychodynamic psychotherapy for anxiety
B: Inclusion Criteria:

1. Over 20 years old
2. Suffering from Axis I disorder
3. Had intent for suicide (confirmed more than 2 times)
4. Able to understand this study and provide informed consent
5. Able to have interview before trial registry and psycho education at hospital
6. Able to have interview for assessment at continuous follow-up care by case manager at the hospital

Exclusion Criteria:

1. Not suffering from Axis I disorder as a primary diagnosis
C: Inclusion Criteria:

* DSM-4 DIBR \>=8 (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Diagnostic inventory for borderline-revised)
D: Inclusion Criteria:

* Outpatients aged 18 to 45 years;
* Diagnoses of BPD according to Diagnostic and Statistical Manual for Mental Disorders (4th version Revised) (DSM-IV-TR) criteria and evaluated by two semi-structured diagnostic interviews
* Structured Clinical Interview for DSM-IV Axis II Disorders (SCID-II) and the Revised Diagnostic Interview for Borderlines (DIB-R)
* Clinical severity measured with Clinical Global Impression for BPD (CGI-BPD) higher than 4;
* Functional impairment measured with a Global Assessment Functioning (GAF) lower than 65.

Exclusion Criteria:

* No severe physical conditions, such as organic brain syndrome or neurological disease that could affect neuropsychological performance;
* Intelligence Quotient (IQ) \< 85;
* Major Depression Disorder (MDD) or substance misuse within the last 6 months;
* Schizophrenia, severe psychotic disorder or bipolar disorder;
* Previous participation in any psychoeducation or cognitive rehabilitation intervention.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Multicenter Trial of Post-Suicide Attempt Case Management for the Prevention of Further Attempts in Japan (ACTION-J)
Brief Summary: This study will determine the effectiveness of continuous follow-up care by case manager in preventing further suicide attempts


Options:
A: Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychosis not otherwise specified or delusional disorder
* Received EASY service for 2 years following a first-episode psychosis
* Cantonese-speaking Chinese
* Ability to understand the study and to provide written informed consent

Exclusion Criteria:

* Organic brain disorder
* Known history of intellectual disability
* Drug-induced psychosis
B: Inclusion Criteria:

* Enrolled patient at Community Psychiatric Clinic (CPC), a large mental health center in urban Seattle, Washington;
* Between 18 and 65 years of age;
* Diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse;
* CPC medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder
* Stimulant drug use one month before enrollment;
* Ability to understand written and spoken English;
* CPC clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study.

Exclusion Criteria:

* Any medical/psychiatric condition, or severity of that condition, that, in the opinion of Dr. Ries, the PI, would compromise safe study participation
* Chart defined organic brain disorder or dementia;
* Current participation in a methadone maintenance program;
* Any other circumstances that in the PI's opinion precludes safe study participation.
C: Inclusion Criteria:

1. Over 20 years old
2. Suffering from Axis I disorder
3. Had intent for suicide (confirmed more than 2 times)
4. Able to understand this study and provide informed consent
5. Able to have interview before trial registry and psycho education at hospital
6. Able to have interview for assessment at continuous follow-up care by case manager at the hospital

Exclusion Criteria:

1. Not suffering from Axis I disorder as a primary diagnosis
D: Inclusion Criteria:

* Age between 18-35 years,
* First-episode schizophrenia og schizotypal disorder in ICD-10,
* Post-acute phase of illness,
* Sufficient comprehension of Danish,
* Written informed consent

Exclusion Criteria:

* Rejection of participation,
* Organic disorder,
* Misuse of psychoactive drugs

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Multicenter Trial of Post-Suicide Attempt Case Management for the Prevention of Further Attempts in Japan (ACTION-J)
Brief Summary: This study will determine the effectiveness of continuous follow-up care by case manager in preventing further suicide attempts


Options:
A: Inclusion Criteria:

* Chronic mental disorder
* Minimum age 18
* Unemployed
* Wants employment
* Must be a recipient of services at one of two participating agencies
* Fluent in English
* Willing and legally able to provide informed consent to participate in study -Subjects with court appointed legal guardians will be included

Exclusion Criteria:

* History of neurological conditions that impair cognition
B: Inclusion Criteria:

* Diagnosis of diabetes and/or heart disease
* Poor disease control (defined as an HbA1c level of at least 8.5%, blood pressure greater than 140/90 mm Hg, LDL cholesterol greater than 130 mg/dL)
* Diagnosis of major depressive disorder

Exclusion Criteria:

* History of psychosis
* At high risk for suicide
* Cognitive impairment
* Current alcohol or substance abuse disorder
* Does not own a telephone
* Currently seeking psychiatric care
* Pregnant or breastfeeding
* Currently enrolled in a Group Health Cooperative disease management program
* Terminal illness
* Plans to leave Group Health Cooperative in less than a year
* Does not speak English
C: Inclusion Criteria:

1. Over 20 years old
2. Suffering from Axis I disorder
3. Had intent for suicide (confirmed more than 2 times)
4. Able to understand this study and provide informed consent
5. Able to have interview before trial registry and psycho education at hospital
6. Able to have interview for assessment at continuous follow-up care by case manager at the hospital

Exclusion Criteria:

1. Not suffering from Axis I disorder as a primary diagnosis
D: Inclusion Criteria:

* Patients with the current diagnosis of Bipolar disorder type I or type II according to current DSM-5 criteria and confirmed with a semi structured interview (SCID).
* Hamilton Depression Scale score under or equal to 8 during the last month.
* Young Mania Rating Scale score under or equal to 6 during the last month.
* No history of relapses during the last 3 previous months but at least 1 relapse during the last year.
* Availability of a telephone account with an unlimited data plan during the 12 following months.

Exclusion Criteria:

* Lack of skills to use the offered smart-phone or unwillingness to learn them.
* FAST score above or equal to 20.
* Past or current participation in psychoeducation groups.
* Obsessive-compulsive disorder according to DSM-5 criteria.
* Concomitant severe medical condition.
* Pregnancy.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Multicenter Trial of Post-Suicide Attempt Case Management for the Prevention of Further Attempts in Japan (ACTION-J)
Brief Summary: This study will determine the effectiveness of continuous follow-up care by case manager in preventing further suicide attempts


Options:
A: Inclusion Criteria:

* Written informed consent
* Surviving a suicide attempt
* Leaving directly the emergency department or hospitalized less than 7 days
* Being able to be joined by telephone mobile

Exclusion Criteria:

* under guardianship
* Patient who are not able to provide a consent
B: Inclusion Criteria:

* Male/female
* Inpatient/outpatient, day care treatment
* German language
* All diagnosis (except: psychosis)
* Written informed consent

Exclusion Criteria

* Psychosis
* Imprisonment
* Foreign languages
C: Inclusion Criteria:

1. Over 20 years old
2. Suffering from Axis I disorder
3. Had intent for suicide (confirmed more than 2 times)
4. Able to understand this study and provide informed consent
5. Able to have interview before trial registry and psycho education at hospital
6. Able to have interview for assessment at continuous follow-up care by case manager at the hospital

Exclusion Criteria:

1. Not suffering from Axis I disorder as a primary diagnosis
D: Inclusion Criteria:

* 18-65 years of age.
* Newly suicide attempt within one month of the inclusion date.
* A minimum of two characteristics in the DSM-IV Borderline Personality Disorder (BPD)
* Informed consent.

Exclusion Criteria:

* Severe depression.
* Bipolar disorder.
* Psychosis within the schizophrenic spectrum.
* Anorexia Nervosa.
* Substance abuse.
* Mental retardation.
* Dementia.
* Lack of informed consent

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Adalimumab for the Treatment of Perianal Fistulas in Crohn's Disease More Effective Alone or Combined to Ciprofloxacin
Brief Summary: To assess whether a combination of ciprofloxacin and adalimumab is more effective than adalimumab alone for the treatment of perianal fistulas in Crohn's disease


Options:
A: Inclusion Criteria:

* proven Crohn's disease
* Single or multiple draining perianal fistulas

Exclusion Criteria:

* Abscesses
* Infliximab, cyclosporine, tacrolimus and antibiotics for Crohn's disease within past 3 months
* active viral infection
* significate cardiovascular dysfunction
* Pregnancy, Lactation
* Surgical bowel resection to be expected within 6 months
* Positive stool culture for enteric pathogens
* Total parental nutrition
B: Inclusion Criteria:

* Subject must have successfully completed either the M02-404 (NCT00077779) or M04-691 (NCT00105300) protocol to be eligible for this study
* Diagnosis of Crohn's disease
* Willing and able to give informed consent

Exclusion Criteria:

* Diagnosis of ulcerative colitis
* Women cannot be pregnant or breastfeeding
* Previous history of listeria infection or untreated tuberculosis
* Previous history of cancer other than successfully treated skin cancer or carcinoma-in-situ of the cervix
C: Inclusion Criteria:

* Subjects who successfully enrolled in and completed the M04-729, (NCT00445939) study

Exclusion Criteria:

* Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study
D: Inclusion Criteria:

* Documented diagnosis of Crohn's disease
* Able to speak and understand English, French or Flemish
* Access to a telephone or email/internet service
* Written informed consent must be obtained and documented

Exclusion Criteria:

* Any conditions (e.g., history of alcohol or substance abuse) which in the opinion of the investigator , may interfere with the patients ability to comply with study procedures
* Participating in other investigational studies

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: GORE VIABAHN® Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients
Brief Summary: The objective of the study is to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface when used to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis.


Options:
A: Inclusion Criteria:

* Hemodialysis patient with a dysfunctional or thrombosed forearm or upper arm prosthetic vascular access graft.
* The target lesion starts less than or equal to 30 mm from the venous anastomosis.
* The target lesion has \> 50% stenosis as measured per protocol.
* The patient has a maximum of one secondary stenosis.

Exclusion Criteria:

* The age of the hemodialysis access graft is less than or equal to 30 days old from the date of the study procedure.
* The patient has undergone an intervention (surgical or percutaneous) of the vascular access circuit less than or equal to 30 days from the date of the study procedure.
* The secondary lesion is an occlusion.
B: Inclusion Criteria:

* Patients with acute thrombosis (\< 10 days) of native or prosthetic AVF.

Exclusion Criteria:

* Known pulmonary hypertension.
* Severe pulmonary disease.
* Low cardiopulmonary reserve.
* Recent creation of vascular access.
* Known right left shunt.
* Access infection.
* Allergy to iodinated contrast.
* Patients under 18 years old.
C: Inclusion Criteria:

* Established dialysis patient with a recent thrombosed AV graft (less than 48 hours).
* AV grafts can be located at the forearm, upper arm or thigh.
* Either first or second episode of thrombosis of the AV graft.
* Stenotic lesion at the venous anastomosis greater than 50% at time of initial intervention.

Exclusion Criteria:

* Established ESRD patients with a recent thrombosed AV fistula.
* Prior participation in this study.
* Prior Stent placement at the venous anastomosis.
* Inability to restore blood flow after mechanical thrombectomy.
* Stenotic lesion at other venous site (i.e. venous outlet or central vessels)
* Three or more prior mechanical thrombectomies and angioplasties of the same graft.
* Stenotic lesion at the venous anastomosis less than 50%
D: Inclusion Criteria:

* Angiographic and clinical diagnosis of dysfunctional dialysis access due to one or more stenotic lesions.
* Patients with AVF or AVG
* Fistula or graft or vessel diameter ranging from 3 mm up to 12 mm

Exclusion Criteria:

* Fistula or graft or vessel diameter \< 3 mm and \> 12 mm
* History of severe allergic reaction to contrast media
* Intolerance to aspirin and/or clopidogrel
* Systemic coagulopathy or hypercoagulation disorders

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children
Brief Summary: An investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in Burkina Faso and Mali.Three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.


Options:
A: Inclusion Criteria:

1. Viable pregnancy assessed by Doppler
2. Gestational age 16 to 32 weeks (inclusive) by fundal height
3. No history of IPTp use during this pregnancy
4. Willing to participate and complete the study schedule
5. Willing to sign or thumb print informed consent
6. Resident of study area and intending to stay in the area for the duration of the follow-up
7. Willing to deliver in the labor ward of the study clinic or hospital
8. HIV negative at enrolment

Exclusion Criteria:

1. HIV positive or unknown
2. Residence outside study area or planning to move out in the 12 months following enrolment
3. High risk pregnancy, including any pre-existing illness likely to cause complication of pregnancy (hypertension, diabetes, asthma, epilepsy, renal disease, liver disease, fistula repair, leg or spine deformity)
4. Severe anemia requiring blood transfusion (Hb ≤ 7.0 g/dL) at enrolment
5. Known allergy or previous adverse reaction to any of the study drugs
6. Unable to give informed consent (for example due to mental disability)
7. Previous inclusion in the same study
8. Gestational age \>32 weeks
9. Previous IPTp during the current pregnancy
10. Participating in other malaria intervention studies
11. Known or suspected cardiac disease
12. Patients taking drugs in any of the following classes: antiarrhythmic agents, neuroleptics, macrolides, and certain antimalarial drugs such as mefloquine, chloroquine, halofantrine and lumefantrine.
B: Inclusion Criteria:

* Permanent residence in the study area with no intention of leaving during the surveillance period.
* Obtention of informed consent.

Exclusion Criteria:

* Temporary residence in the study area.
* Absence of informed consent.
* Presence of a severe, chronic illness such as severe malnutrition (Kwashiorkor or marasmus) or AIDS, likely to interfere with evaluation of the trial results.
* A history of a previous, significant adverse reaction to either of the study drugs.
C: Inclusion Criteria:

* Resident of Kolokani, Mali
* Age less than 24 months

Exclusion Criteria:

* Not Resident of Kolokani
* Age of 24 months or above
D: Inclusion Criteria:

* Informed consent
* Permanent residence in the study area

Exclusion Criteria:

* Allergy/hypersensitivity to sulfonamides or pyrimethamine
* Signs of severe hepatic or renal dysfunction not due to malaria

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children
Brief Summary: An investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in Burkina Faso and Mali.Three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.


Options:
A: Inclusion Criteria:

* Enrolled in primary school, and attending regularly
* Enrolled in nursery or classes 1-7
* Informed consent from parent or guardian

Exclusion Criteria:

* Enrolled in primary class 8
* Haemoglobin level below 70g/L at baseline
* History of reaction to sulfa drugs (e.g. fansidar, septrin)
* History of severe skin reaction to any drug

Withdrawal criteria:

* Withdrawal of parental consent
* Haemoglobin level falling below 70g/L
* Severe adverse reaction to treatment
B: Inclusion Criteria:

* Permanent residence in the study area with no intention of leaving during the surveillance period.
* Obtention of informed consent.

Exclusion Criteria:

* Temporary residence in the study area.
* Absence of informed consent.
* Presence of a severe, chronic illness such as severe malnutrition (Kwashiorkor or marasmus) or AIDS, likely to interfere with evaluation of the trial results.
* A history of a previous, significant adverse reaction to either of the study drugs.
C: Inclusion Criteria:

* permanent resident of the research area
* age \>1 years

Exclusion Criteria:

* severe anemia
* pregnancy
D: Inclusion Criteria:

* Ages 1 - 5 years
* Residence in the study area
* Informed consent

Exclusion Criteria:

* Known allergy to study drugs
* Chronic, underlying illness

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children
Brief Summary: An investigation will be made of the combined impact of insecticide-treated nets and intermittent preventive treatment with amodiaquine + sulfadoxine-pyrimethamine on malaria morbidity in children in Burkina Faso and Mali.Three rounds of treatment will be given during the malaria season in one year and the follow-up will be extended into the second year by passive surveillance.


Options:
A: Inclusion Criteria:

* All infants attending EPI clinics at the 12 study health facilities for first vaccinations. Infants who live within the catchment area of the study health facility and are less than 3 months of age at the time of DPT and Polio 1 vaccination will be eligible for inclusion in the study.

Exclusion Criteria:

* Infants having any of the following conditions will be excluded: (1) history of allergy to study drugs; (2) history of convulsions; (3) clinical features of severe malnutrition or chronic illness including infants with signs of AIDS \[HIV prevalence in women of reproductive age in the study area was 11.5% in 1999\]39 (4) plans to leave the study area before 12 months of age.(5) weighs \<4.5 kgs (6) caretaker declines to give consent.
B: Inclusion Criteria:

* Permanent residence in the study area with no intention of leaving during the surveillance period.
* Obtention of informed consent.

Exclusion Criteria:

* Temporary residence in the study area.
* Absence of informed consent.
* Presence of a severe, chronic illness such as severe malnutrition (Kwashiorkor or marasmus) or AIDS, likely to interfere with evaluation of the trial results.
* A history of a previous, significant adverse reaction to either of the study drugs.
C: Inclusion Criteria:

1. Age between 3 months and 59 months at enrolment.
2. Informed consent obtained from parents or legal guardians.
3. No current participation in another malaria intervention trial
4. Permanent residence in the study area with no intention of leaving during the surveillance period.

Exclusion Criteria:

1. Previous adverse reaction to treatment with SP, amodiaquine or Coartem. If this is unknown, then a history of allergic reaction to any drug.
2. Temporary residence in the study area
3. Lack of informed consent
4. Presence of a severe, chronic illness such as severe malnutrition or AIDS, likely to interfere with evaluation of the trial results.
D: Inclusion Criteria:

* Informed consent
* Permanent residence in the study area

Exclusion Criteria:

* Allergy/hypersensitivity to sulfonamides or pyrimethamine
* Signs of severe hepatic or renal dysfunction not due to malaria

Answer: B